De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

RemeGen Beheer

Beheer criteriumcontroles 3/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Jianmin Fang

Algemeen directeur

CN¥14.7m

Totale compensatie

Percentage CEO-salaris	37.0%
Dienstverband CEO	16yrs
Eigendom CEO	11.4%
Management gemiddelde ambtstermijn	2.8yrs
Gemiddelde ambtstermijn bestuur	4.4yrs

Recente managementupdates

Here's Why Shareholders May Want To Be Cautious With Increasing RemeGen Co., Ltd.'s (HKG:9995) CEO Pay Packet

Jun 21

Recent updates

Improved Revenues Required Before RemeGen Co., Ltd. (HKG:9995) Stock's 31% Jump Looks Justified

Sep 28

RemeGen Co., Ltd. (HKG:9995) Just Reported Earnings, And Analysts Cut Their Target Price

Aug 20

Benign Growth For RemeGen Co., Ltd. (HKG:9995) Underpins Stock's 41% Plummet

Jul 22

Here's Why Shareholders May Want To Be Cautious With Increasing RemeGen Co., Ltd.'s (HKG:9995) CEO Pay Packet

Jun 21

RemeGen Co., Ltd.'s (HKG:9995) Shares Climb 35% But Its Business Is Yet to Catch Up

Apr 04

Is RemeGen (HKG:9995) Using Debt In A Risky Way?

Mar 24

RemeGen Co., Ltd. (HKG:9995) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely

Feb 18

Getting In Cheap On RemeGen Co., Ltd. (HKG:9995) Is Unlikely

Dec 29

RemeGen Co., Ltd. (HKG:9995) Shares Could Be 34% Below Their Intrinsic Value Estimate

Oct 16

RemeGen Co., Ltd. (HKG:9995) Analysts Just Cut Their EPS Forecasts Substantially

Apr 08

RemeGen Co., Ltd. (HKG:9995) Just Reported And Analysts Have Been Cutting Their Estimates

Feb 23

We're Hopeful That RemeGen (HKG:9995) Will Use Its Cash Wisely

Jan 21

Are Investors Undervaluing RemeGen Co., Ltd. (HKG:9995) By 42%?

Nov 30

We're Hopeful That RemeGen (HKG:9995) Will Use Its Cash Wisely

Oct 16

A Look At The Intrinsic Value Of RemeGen Co., Ltd. (HKG:9995)

Aug 24

Analyse CEO-vergoeding

Hoe is Jianmin Fang's beloning veranderd ten opzichte van RemeGen's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-CN¥2b
Mar 31 2024	n/a	n/a	-CN¥2b
Dec 31 2023	CN¥15m	CN¥5m	-CN¥2b
Sep 30 2023	n/a	n/a	-CN¥1b
Jun 30 2023	n/a	n/a	-CN¥1b
Mar 31 2023	n/a	n/a	-CN¥1b
Dec 31 2022	CN¥27m	CN¥5m	-CN¥999m
Sep 30 2022	n/a	n/a	CN¥276m
Jun 30 2022	n/a	n/a	CN¥231m
Mar 31 2022	n/a	n/a	CN¥174m
Dec 31 2021	CN¥8m	CN¥4m	CN¥276m

Compensatie versus markt: De totale vergoeding ($USD 2.09M ) Jianmin } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Hong Kong markt ($USD 564.92K ).

Compensatie versus inkomsten: De vergoeding van Jianmin is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Jianmin Fang (61 yo)

16yrs

Tenure

CN¥14,658,000

Compensatie

Dr. Jianmin Fang is Co-Founder at RemeGen Co. Ltd. He has been Director, Chief Executive Officer and GM of RemeGen Co. Ltd. and served as its Chief Scientific Officer since October 16, 2008 to 2023 and red...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Weidong Wang	Co-Founder & Executive Chairman	11yrs	CN¥15.15m	geen gegevens
Jianmin Fang	Co-Founder	16yrs	CN¥14.66m	11.44% CN¥ 1.9b
Shaojing Tong	CFO & Joint Company Secretary	1.1yrs	CN¥1.25m	geen gegevens
Ruyi He	Chief Medical Officer	no data	CN¥24.01m	0.00090% CN¥ 152.2k
Jian Lin	Executive Director	no data	CN¥1.13m	geen gegevens
Kaisheng Huang	Chief Operating Officer	no data	geen gegevens	geen gegevens
Marie Zhu	Chief Technical Officer	no data	geen gegevens	geen gegevens
Zhulun Wang	Chief Scientific Officer	no data	geen gegevens	geen gegevens
Daniel Ross	Chief Business Officer	less than a year	geen gegevens	geen gegevens
Xiaoming Yang	Chief Manufacturing Officer	no data	geen gegevens	geen gegevens
Qingkai Wen	Board Secretary	4.4yrs	geen gegevens	geen gegevens

2.8yrs

Gemiddelde duur

61yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 9995 wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Weidong Wang	Co-Founder & Executive Chairman	11yrs	CN¥15.15m	geen gegevens
Jianmin Fang	Co-Founder	16yrs	CN¥14.66m	11.44% CN¥ 1.9b
Ruyi He	Chief Medical Officer	4.4yrs	CN¥24.01m	0.00090% CN¥ 152.2k
Jian Lin	Executive Director	16.3yrs	CN¥1.13m	geen gegevens
Lorne Alan Babiuk	Member of Scientific Advisory Board	no data	CN¥125.00k	geen gegevens
Gang Pei	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Liqiang Wang	Non-Executive Director	4.4yrs	geen gegevens	4.69% CN¥ 793.0m
Xiaodi Su	Non-Executive Director	4.4yrs	geen gegevens	geen gegevens
Xianjing Hao	Independent Non-Executive Director	4.4yrs	CN¥300.00k	geen gegevens
Guangke Ren	Chairman of the Supervisory Board	4.4yrs	geen gegevens	geen gegevens
Lan Ma	Independent Non-Executive Director	3.3yrs	CN¥300.00k	geen gegevens
Yunjin Chen	Independent Non-Executive Director	2.4yrs	CN¥300.00k	geen gegevens

4.4yrs

Gemiddelde duur

61yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 9995 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.4 jaar).

RemeGen Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Here's Why Shareholders May Want To Be Cautious With Increasing RemeGen Co., Ltd.'s (HKG:9995) CEO Pay Packet

RemeGen Co., Ltd., Annual General Meeting, Jun 28, 2024

Remegen Co., Ltd. Appoints Tong Shaojing as Joint Company Secretary

Remegen Co., Ltd. Announces Resignation of Li Jia as Chief Financial Officer

RemeGen Co., Ltd. Announces Resignation of Li Jia as Joint Company Secretary

Less than half of directors are independent

Recent updates

New major risk - Share price stability

RemeGen Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Improved Revenues Required Before RemeGen Co., Ltd. (HKG:9995) Stock's 31% Jump Looks Justified

New major risk - Market cap size

Consensus EPS estimates fall by 20%, revenue upgraded

New major risk - Financial position

RemeGen Co., Ltd. (HKG:9995) Just Reported Earnings, And Analysts Cut Their Target Price

Second quarter 2024 earnings released: CN¥0.80 loss per share (vs CN¥0.70 loss in 2Q 2023)

RemeGen Co., Ltd. Announces First Patient Enrollment in the U.S for Its Global Multi-Center Phase III Clinical Trial for the Treatment of Generalized Myasthenia Gravis

Benign Growth For RemeGen Co., Ltd. (HKG:9995) Underpins Stock's 41% Plummet

RemeGen Co., Ltd. Announces Full Approval of Telitacicept for the Treatment of Patients with Rheumatoid Arthritis by NMPA

New minor risk - Profitability

New minor risk - Share price stability

RemeGen Co., Ltd. to Report First Half, 2024 Results on Aug 17, 2024

Here's Why Shareholders May Want To Be Cautious With Increasing RemeGen Co., Ltd.'s (HKG:9995) CEO Pay Packet

RemeGen Co., Ltd. Announces Phase III Clinical Study of Disitamab Vedotin for Injection for the Treatment of HER2-Positive Advanced Breast Cancer with Liver Metastasis Met Primary Study Endpoint

RemeGen Co., Ltd., Annual General Meeting, Jun 28, 2024

RemeGen Co., Ltd.'s (HKG:9995) Shares Climb 35% But Its Business Is Yet to Catch Up

Full year 2023 earnings released: CN¥2.80 loss per share (vs CN¥1.88 loss in FY 2022)

New minor risk - Profitability

RemeGen Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Is RemeGen (HKG:9995) Using Debt In A Risky Way?

RemeGen Co. Ltd. Presents Oral Presentation on Evaluation of its Proprietary Disitamab Vedotin (RC48) for Cervical Cancer At ESGO 2024

Full year 2023 earnings released: CN¥2.86 loss per share (vs CN¥1.88 loss in FY 2022)

RemeGen Co., Ltd. (HKG:9995) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely

RemeGen Co., Ltd. Provides Earnings Guidance for the Period from January 1, 2023 to December 31, 2023

RemeGen Co., Ltd. Provides Earnings Guidance for the Period from January 1, 2023 to December 31, 2023

New minor risk - Share price stability

RemeGen's Rc88 Obtains FDA Fast Track Designation, Heralds New Hope for Ovarian Cancer Patients

Getting In Cheap On RemeGen Co., Ltd. (HKG:9995) Is Unlikely

RemeGen Co., Ltd.'s Pioneering RC88 Receives IND Approval from US FDA for Platinum-Resistant Recurrent Ovarian Cancer Treatment

RemeGen Co., Ltd. Announces the Full Approval of. Telitacicept for. Systemic Lupus erythematosus by NMPA

RemeGen Co., Ltd. to Present telitacicept Phase III Clinical Trial Results for Rheumatoid Arthritis Patients in A Late-Breaking Abstract Oral Presentation Session At the American College of Rheumatology

Third quarter 2023 earnings released

RemeGen Co., Ltd. (HKG:9995) Shares Could Be 34% Below Their Intrinsic Value Estimate

Remegen Co., Ltd. Appoints Tong Shaojing as Joint Company Secretary

Remegen Co., Ltd. Announces Resignation of Li Jia as Chief Financial Officer

RemeGen Co., Ltd. Announces Resignation of Li Jia as Joint Company Secretary

Second quarter 2023 earnings released: CN¥0.70 loss per share (vs CN¥0.38 loss in 2Q 2022)

RemeGen Co., Ltd. Announces Results of Phase III Study on Telitacicept for Treatment of Rheumatoid Arthritis in China

Is RemeGen (HKG:9995) In A Good Position To Invest In Growth?

New minor risk - Share price stability

RemeGen Co., Ltd. to Report First Half, 2023 Results on Aug 22, 2023

Is There An Opportunity With RemeGen Co., Ltd.'s (HKG:9995) 35% Undervaluation?

Now 20% undervalued after recent price drop

RemeGen Co., Ltd. (HKG:9995) Investors Are Less Pessimistic Than Expected

Remegen Co., Ltd. Receives Ethics Approval for the Phase I Clinical Trial in Australia

Now 21% undervalued after recent price drop

Are Investors Undervaluing RemeGen Co., Ltd. (HKG:9995) By 36%?

Full year 2022 earnings released: CN¥1.81 loss per share (vs CN¥0.57 profit in FY 2021)

Now 20% undervalued

RemeGen Co., Ltd. Announces FDA Approves Ind Application for Telitacicept for Treatment of gMG and Grants It Fast Track Designation

National Medical Products Administration Approves IND Application for RemeGen’s Disitamab Vedotin for Injection, Given Intravenously, in Combination with Gemcitabine Hydrochloride for Injection, Given Intravesically, for Treatment of NMIBC

RemeGen Co., Ltd.'s RC118 for Injection Targeting Claudin 18.2 in Patients with Gastric and Pancreatic Cancers Granted Two Orphan Drug Designations by U.S. FDA

Less than half of directors are independent

RemeGen Co., Ltd. Announces Telitacicept Propose to Grant Telitacicept Breakthrough Therapy Designation for the Treatment of Generalised Myasthenia Gravis

RemeGen Co., Ltd. Announces Results of Phase Ii Clinical Study of Telitacicept for Treatment of Myasthenia Gravis (MG) in China

Third quarter 2022 earnings released: CN¥0.37 loss per share (vs CN¥0.74 profit in 3Q 2021)

RemeGen Co., Ltd. to Report Nine Months, 2022 Results on Oct 27, 2022

Remegen Co., Ltd. Receives Orphan Drug Designation from FDA for Treatment of Myasthenia Gravis

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

RemeGen Co., Ltd. Announces Preliminary Result of Telitacicept in the Phase III Comfirmatory Study to Treat Systemic Lupus Erythematosus in China

Second quarter 2022 earnings released

RemeGen Co., Ltd. to Report Q2, 2022 Results on Aug 26, 2022

RemeGen Co., Ltd., Annual General Meeting, Jun 29, 2022

RemeGen Co., Ltd. Approves Appointment of Chen Yunjin as Independent Non-Executive Director

RemeGen's (HKG:9995) Earnings Aren't As Good As They Appear

Less than half of directors are independent